What potential do heterobivalent inhibitors have for the treatment of severe allergic reactions?

Immunotherapy. 2014;6(3):223-5. doi: 10.2217/imt.14.1.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Allergens / administration & dosage
  • Allergens / immunology
  • Animals
  • Anti-Allergic Agents / chemical synthesis
  • Anti-Allergic Agents / immunology
  • Anti-Allergic Agents / therapeutic use*
  • Antibody Affinity
  • Antibody Specificity
  • Antigen-Antibody Reactions / drug effects
  • Binding Sites, Antibody
  • Desensitization, Immunologic
  • Drug Design
  • Drug Evaluation, Preclinical
  • Half-Life
  • Haptens / immunology
  • Histamine Release / drug effects
  • Humans
  • Hypersensitivity, Immediate / drug therapy
  • Hypersensitivity, Immediate / immunology
  • Hypersensitivity, Immediate / prevention & control*
  • Immunodominant Epitopes / immunology
  • Immunoglobulin E / immunology*
  • Immunoglobulin Fab Fragments / immunology
  • Indoles / chemical synthesis
  • Indoles / therapeutic use*
  • Ligands
  • Mast Cells / metabolism
  • Nitrofurans / chemical synthesis
  • Nitrofurans / therapeutic use*

Substances

  • Allergens
  • Anti-Allergic Agents
  • Haptens
  • Immunodominant Epitopes
  • Immunoglobulin Fab Fragments
  • Indoles
  • Ligands
  • Nitrofurans
  • Immunoglobulin E